Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homing potential of vaccine antigen-specific B-cell and antibody responses after vaccination
2010-023313-57Phase 4Completed
- Sponsor
- Helsinki University Hospital
- Start
- Mar 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated), IDflu, cholera toxin B subunit, typhoid vaccine, live oral, salmonella typhi capsular polysaccharide vaccine and 6 more in Infectious disease (11 arms), sponsored by Helsinki University Hospital. Started Mar 2012; status: completed.
02
Drugs
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)IDflucholera toxin B subunittyphoid vaccine, live oralsalmonella typhi capsular polysaccharide vaccine
03
Conditions
Infectious disease
Beyond the preview
Go deeper on 2010-023313-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023313-57.